Applied DNA Sciences Statistics
Share Statistics
Applied DNA Sciences has 52.29M shares outstanding. The number of shares has increased by 208% in one year.
| Shares Outstanding | 52.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 407.74% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 52.28M |
| Failed to Deliver (FTD) Shares | 421.99K |
| FTD / Avg. Volume | 6.72% |
Short Selling Information
The latest short interest is 1.77M, so 3.39% of the outstanding shares have been sold short.
| Short Interest | 1.77M |
| Short % of Shares Out | 3.39% |
| Short % of Float | 3.39% |
| Short Ratio (days to cover) | 0.47 |
Valuation Ratios
The PE ratio is -0.36 and the forward PE ratio is -0.18.
| PE Ratio | -0.36 |
| Forward PE | -0.18 |
| PS Ratio | 0.75 |
| Forward PS | null |
| PB Ratio | 0.28 |
| P/FCF Ratio | -0.18 |
| PEG Ratio | n/a |
Enterprise Valuation
Applied DNA Sciences Inc. has an Enterprise Value (EV) of 310.51M.
| EV / Earnings | -42.97 |
| EV / Sales | 90.49 |
| EV / EBITDA | -22.14 |
| EV / EBIT | -22.14 |
| EV / FCF | -21.99 |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.36 |
| Quick Ratio | 3.17 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.48 |
| Cash Flow / Debt | -18.55 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.79% and return on capital (ROIC) is -147.28%.
| Return on Equity (ROE) | -0.79% |
| Return on Assets (ROA) | -0.56% |
| Return on Capital (ROIC) | -147.28% |
| Revenue Per Employee | 65.99K |
| Profits Per Employee | -138.95K |
| Employee Count | 52 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 5.51 |
Taxes
| Income Tax | 137.30K |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by -98.5% in the last 52 weeks. The beta is 0.45, so Applied DNA Sciences 's price volatility has been higher than the market average.
| Beta | 0.45 |
| 52-Week Price Change | -98.5% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 1.5 |
| Relative Strength Index (RSI) | 44.39 |
| Average Volume (20 Days) | 6.28M |
Income Statement
In the last 12 months, Applied DNA Sciences had revenue of 3.43M and earned -7.23M in profits. Earnings per share was -1.82.
| Revenue | 3.43M |
| Gross Profit | 1.02M |
| Operating Income | -14.02M |
| Net Income | -7.23M |
| EBITDA | -14.02M |
| EBIT | -14.02M |
| Earnings Per Share (EPS) | -1.82 |
Balance Sheet
The company has 6.43M in cash and 739.16K in debt, giving a net cash position of 5.69M.
| Cash & Cash Equivalents | 6.43M |
| Total Debt | 739.16K |
| Net Cash | 5.69M |
| Retained Earnings | -309.67M |
| Total Assets | 12.79M |
| Working Capital | 5.65M |
Cash Flow
In the last 12 months, operating cash flow was -13.71M and capital expenditures -407.90K, giving a free cash flow of -14.12M.
| Operating Cash Flow | -13.71M |
| Capital Expenditures | -407.90K |
| Free Cash Flow | -14.12M |
| FCF Per Share | -3.56 |
Margins
Gross margin is 29.63%, with operating and profit margins of -408.72% and -210.57%.
| Gross Margin | 29.63% |
| Operating Margin | -408.72% |
| Pretax Margin | -206.57% |
| Profit Margin | -210.57% |
| EBITDA Margin | -408.72% |
| EBIT Margin | -408.72% |
| FCF Margin | -411.47% |
Dividends & Yields
APDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1011.11% |
| FCF Yield | -148.02% |
Analyst Forecast
The average price target for APDN is $1.5, which is 733.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $1.5 |
| Price Target Difference | 733.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 25, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 25, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -34.82 |
| Piotroski F-Score | 4 |